Tempus to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference
Tempus AI (NASDAQ: TEM), a leader in AI-driven precision medicine, is set to participate in the Morgan Stanley 22nd Annual Global Healthcare Conference on September 4, 2024, in New York. The company's Founder and CEO, Eric Lefkofsky, will engage in a fireside discussion at 8:30 a.m. ET during the event.
This participation highlights Tempus' commitment to advancing healthcare through technology and AI. The conference provides a platform for Tempus to showcase its innovations and discuss the future of precision medicine with industry leaders and investors.
Tempus AI (NASDAQ: TEM), un leader nella medicina di precisione alimentata dall'IA, parteciperà alla 22ª Conferenza Globale sulla Sanità Annuale di Morgan Stanley il 4 settembre 2024 a New York. Il fondatore e CEO dell'azienda, Eric Lefkofsky, parteciperà a una discussione informale alle 8:30 ET durante l'evento.
Questa partecipazione sottolinea l'impegno di Tempus nel promuovere la sanità attraverso la tecnologia e l'IA. La conferenza offre una piattaforma per Tempus per mostrare le sue innovazioni e discutere il futuro della medicina di precisione con leader del settore e investitori.
Tempus AI (NASDAQ: TEM), un líder en medicina de precisión impulsada por IA, participará en la 22ª Conferencia Anual Global de Atención Médica de Morgan Stanley el 4 de septiembre de 2024 en Nueva York. El fundador y CEO de la empresa, Eric Lefkofsky, participará en una discusión informal a las 8:30 a.m. ET durante el evento.
Esta participación destaca el compromiso de Tempus con el avance de la atención médica a través de la tecnología y la IA. La conferencia ofrece una plataforma para que Tempus muestre sus innovaciones y discuta el futuro de la medicina de precisión con líderes de la industria e inversores.
템푸스 AI (NASDAQ: TEM)는 AI 기반 정밀 의학의 선두주자로서 2024년 9월 4일 뉴욕에서 열리는 모건 스탠리 제22회 글로벌 헬스케어 컨퍼런스에 참가할 예정입니다. 회사의 창립자이자 CEO인 에릭 레프코프스키는 행사 중 오전 8시 30분(ET)에 대화에 참여할 것입니다.
이번 참여는 기술과 AI를 통해 헬스케어를 발전시키려는 템푸스의 의지를 강조합니다. 이 컨퍼런스는 템푸스가 자신의 혁신을 선보이고 업계 리더 및 투자자들과 함께 정밀 의학의 미래에 대해 논의할 수 있는 플랫폼을 제공합니다.
Tempus AI (NASDAQ: TEM), un leader en médecine de précision pilotée par l'IA, participera à la 22ème Conférence Annuelle Mondiale sur la Santé de Morgan Stanley le 4 septembre 2024 à New York. Le fondateur et PDG de l'entreprise, Eric Lefkofsky, participera à une discussion informelle à 8h30 ET durant l'événement.
Cette participation met en lumière l'engagement de Tempus à faire progresser les soins de santé grâce à la technologie et à l'IA. La conférence offre une plateforme à Tempus pour présenter ses innovations et discuter de l'avenir de la médecine de précision avec des leaders de l'industrie et des investisseurs.
Tempus AI (NASDAQ: TEM), ein führendes Unternehmen in der KI-gestützten Präzisionsmedizin, wird am 4. September 2024 an der 22. jährlichen globalen Gesundheitskonferenz von Morgan Stanley in New York teilnehmen. Der Unternehmensgründer und CEO, Eric Lefkofsky, wird um 8:30 Uhr ET an einer informellen Diskussion während der Veranstaltung teilnehmen.
Diese Teilnahme unterstreicht das Engagement von Tempus, die Gesundheitsversorgung durch Technologie und KI voranzubringen. Die Konferenz bietet eine Plattform, um Tempus' Innovationen zu präsentieren und die Zukunft der Präzisionsmedizin mit Branchenführern und Investoren zu erörtern.
- None.
- None.
Tempus Founder and CEO, Eric Lefkofsky, will speak in a fireside discussion at the conference on Wednesday, September 4, 2024 at 8:30 a.m. ET.
About Tempus
Tempus is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. With one of the world’s largest libraries of multimodal data, and an operating system to make that data accessible and useful, Tempus provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics. The goal is for each patient to benefit from the treatment of others who came before by providing physicians with tools that learn as the company gathers more data. For more information, visit tempus.com.
Forward Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended, about Tempus and Tempus’ industry that involve substantial risks and uncertainties. All statements other than statements of historical facts contained in this press release are forward-looking statements, including, but not limited to, statements regarding Tempus’ and its employee’s potential future speaking engagements. In some cases, you can identify forward-looking statements because they contain words such as “anticipate,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “going to,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” or “would” or the negative of these words or other similar terms or expressions. Tempus cautions you that the foregoing may not include all of the forward-looking statements made in this press release.
You should not rely on forward-looking statements as predictions of future events. Tempus has based the forward-looking statements contained in this press release primarily on its current expectations and projections about future events and trends that it believes may affect Tempus’ business, financial condition, results of operations and prospects. These forward-looking statements are subject to risks and uncertainties related to: Tempus’ financial performance; the ability to attract and retain customers and partners; managing Tempus’ growth and future expenses; competition and new market entrants; compliance with new laws, regulations and executive actions, including any evolving regulations in the artificial intelligence space; the ability to maintain, protect and enhance Tempus’ intellectual property; the ability to attract and retain qualified team members and key personnel; the ability to repay or refinance outstanding debt, or to access additional financing; future acquisitions, divestitures or investments; the potential adverse impact of climate change, natural disasters, health epidemics, macroeconomic conditions, and war or other armed conflict, as well as risks, uncertainties, and other factors described in the section titled “Risk Factors” in Tempus’ Quarterly Report on Form 10-Q for the quarter ended June 30, 2024 filed with the Securities and Exchange Commission (“SEC”) as well as in other filings Tempus may make with the SEC in the future. In addition, any forward-looking statements contained in this press release are based on assumptions that Tempus believes to be reasonable as of this date. Tempus undertakes no obligation to update any forward-looking statements to reflect events or circumstances after the date of this press release or to reflect new information or the occurrence of unanticipated events, except as required by law.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240828801131/en/
Tempus Investor Relations
Elizabeth Krutoholow
Elizabeth.krutoholow@tempus.com
Source: Tempus AI, Inc.
FAQ
When is Tempus AI (TEM) presenting at the Morgan Stanley Healthcare Conference?
Who will be representing Tempus AI (TEM) at the Morgan Stanley Healthcare Conference?
What is the focus of Tempus AI's (TEM) business?
Where is the Morgan Stanley Global Healthcare Conference being held?
